Alaina Geren, MD
Ophthalmology · Leawood, KSNPI 1790272417
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Alcon at 48.4% of the total.
Across 84 payments — averaging $53.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Biotissue Holdings Inc.$559
- Bausch & Lomb Americas Inc.$417
- Glaukos Corporation$236
- ANI Pharmaceuticals, Inc.$199
- Dompe US, Inc.$182
- plus $719 from 10 others
What the payments were for
- Travel & lodging$4159%
- Food & beverage$4,06191%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $2,170 |
| Biotissue Holdings Inc. | 6 | $559 |
| Bausch & Lomb Americas Inc. | 8 | $417 |
| Glaukos Corporation | 3 | $236 |
| ANI Pharmaceuticals, Inc. | 7 | $199 |
| Dompe US, Inc. | 4 | $182 |
| Mallinckrodt Hospital Products Inc. | 8 | $160 |
| Sun Pharmaceutical Industries Inc. | 3 | $152 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $109 |
| Alimera Sciences, Inc. | 1 | $97 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Genentech USA, Inc. | 2 | $44 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Amgen | 1 | $19 |
| Rxsight Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$660
- Clareon PanOptix Pro$288
- AcrySof IQ PanOptix UV IOL$280
- AcrySof IQ VIVITY$149
- enVista MX60 IOL$125
- CEQUA$120
- Oxervate$118
- MIEBO$115
- XIIDRA$115
- Tecnis Simplicity$109
- KXL System$108
- PHOTREXA CROSS-LINKING KIT$108
How this compares
$4,483 in reported general payments places this provider in the 80th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 56 | $64,215 |
| XdemvyLotilaner | 16 | $30,679 |
| XiidraLifitegrast | 31 | $26,270 |
| Cyclosporine | 35 | $16,148 |
| CequaCyclosporine | 15 | $11,517 |
| Prednisolone Acetate | 340 | $11,061 |
| Restasis MultidoseCyclosporine | 17 | $9,510 |
| Loteprednol Etabonate | 32 | $5,150 |
| TobradexTobramycin/Dexamethasone | 14 | $3,784 |
| ValacyclovirValacyclovir Hcl | 54 | $2,576 |
| Fluorometholone | 31 | $2,372 |
| Ofloxacin | 185 | $2,254 |
| ErythromycinErythromycin Base | 123 | $1,425 |
| MoxifloxacinMoxifloxacin Hcl | 39 | $1,268 |
| Doxycycline Hyclate | 39 | $1,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $55 | $30,67916 claims |
| Bausch & Lomb Americas Inc.Xiidra | $417 | $26,27031 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $152 | $11,51715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Leawood
- John DoaneLeawood$496K
- Matthew SniegowskiLeawood$22K
- Timothy WallineLeawood$5K
- Kevin PikeyLeawood$3K
- Alexander VuLeawood$2K
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.